Phase 2 · NCT04867785
A Study of LY3437943 in Participants With Type 2 Diabetes
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
CompletedVerified
Registry record
Trial details
- Trial
- A Study of LY3437943 in Participants With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT04867785
- Indication
- Type 2 Diabetes
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 281
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Dulaglutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – 75 Years
- Locations
- 43 sites · Puerto Rico, United States
- Study start
- 13 May 2021
- Primary completion
- 8 Jul 2022
- Study completion
- 27 Oct 2022
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 3 Jul 2023
Endpoints
Primary
Change From Baseline in Hemoglobin A1c (HbA1c)
Secondary
Change From Baseline in HbA1c; Change From Baseline in HbA1c; Percentage of Participants Reaching HbA1c <7.0%; Percentage of Participant Reaching HbA1c <7.0%; Change From Baseline in Fasting Blood Glucose (FBG); Change From Baseline in Fasting Blood Glucose (FBG); Change From Baseline in Body Weight; Change From Baseline in Body Weight; Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943